Conduct↦Management↦Responsibility and Oversight↦Drug and Device Accountability
What is it? Why is it important?
Drug and Device Accountability (DDA) refers to the documentation and management (e.g. shipment, storage, preparation, use, destruction) of an Investigational Product (IP) (e.g. an IMP and/or IMD).
For a SP-INV, IP accountability:
- Starts once the IP is ordered from a Manufacturing Authorisation Holder (MAH), followed by the distribution to participating study sites
- Ends with IP destruction, which can also be the end of a required archiving period
For a Site-INV, IP accountability:
- Starts once the IP has been delivered to the study site
- Continues to be tracked during study conduct, such as when the IP is:
- Removed from storage, or prepared and delivered by a hospital pharmacy
- Distributed to study participants
- Returned by participants to the study site (e.g. compliance check)
- Ends with used / not used IP being returned to the SP-INV or destroyed at the site
More
IP oversight also includes a:
- Collaboration with IP providers (e.g. MAH, pharmacy)
- Faultless storage of IP based on IP instruction for use, and SP-INV specifications (e.g. required storage temperature, humidity, light)
- Restricted access to IP-storage sites (e.g. study site delegation-log). This ensures that the DDA-log remains current and correct, and IP is protected against accidental loss or damage
- Faultless IP dispensing to study participants (e.g. IP preparation, IP labelling information, IP dosage escalations, removal of damaged IP, faultless execution)
- Faultless ongoing IP documentation. This includes the proof that any placebo or comparator was handled and administered according to the study protocol
DDA-logs are subject to reviews during study monitoring visits, and potential RA inspections (e.g. Swissmedic).
What do I need to do?
As a SP-INV, implement DDA procedures and document IP:
- Ordered and received by licensed providers (e.g. pharmacy, manufacturer)
- Distributed to study sites
- Use during study conduct (e.g. based on the monitoring of IP use by study participants – used/not used)
- Expiration and any stability testing during study conduct
- Returned from participating study sites, including its destruction
As a Site-INV, maintain ongoing oversight of IP-Inventory and use. Document ongoing:
- IP delivered to the study site (e.g. on behalf of the SP-INV)
- IP handed out and returned by study participants (e.g. IP-Accountability-Log and IP-Destruction-Log)
As a Site-INV, manage IP storage, such as to:
- Ensure ongoing optimal storage conditions
- Check for expired IPs and if applicable:
- Send expired IPs for stability testing
- Relabel IPs based on a newly approved expiration date
- Return unused or expired IPs to the SP-INV, or destroy IPs based on SP-INV SOPs
More
As a Site-INV, during study conduct:
- Keep empty IP blisters, vials, or bottles until the study monitor has documented its use. This information enables the SP-INV to perform IP accountability controls during study monitoring visits (e.g. use is tracked based on which study participant received and used which IP lot/serial number)
- In the event IPs are destroyed at the study site, provide the SP-INV with a certificate of destruction
IP accountability ends upon IP destruction, implemented after a required archiving period
Where can I get help?
Your local CTU↧ can support you with experienced staff regarding this topic
Basel, Departement Klinische Forschung, CTU, dkf.unibas.ch
Lugano, Clinical Trials Unit, CTU-EOC, www.ctueoc.ch
Bern, Clinical Trials Unit, CTU, www.ctu.unibe.ch
Geneva, Clinical Research Center, CRC, crc.hug.ch
Lausanne, Clinical Research Center, CRC, www.chuv.ch
St. Gallen, Clinical Trials Unit, CTU, www.kssg.ch
Zürich, Clinical Trials Center, CTC, www.usz.ch
References
ICH GCP E6(R2) – see in particular guidelines
- 4.6 Investigational product(s)
- 5.14 Supplying and handling investigational products(s)
- 8.3.23 During the Clinical Conduct of the Trial
ISO 14155:2020 Medical devices (access liable to cost) - see in particular section
- 7.9 Investigational device accountability